Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ASCVD Clear all
Recruiting Not applicable Interventional

Penn Medicine Healthy Heart

NCT06062394
View directory record Official record
Conditions
Hypertension, Hyperlipidemias
Interventions
Penn Med Healthy Heart Program
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
35 Years to 80 Years
Enrollment
1,980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

NCT03889314
View directory record Official record
Conditions
Cardiovascular Risk Factor, Cardiovascular Diseases, Adverse Effect
Interventions
Rosuvastatin 20mg, Placebo
Drug · Other
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 23, 2026, 2:17 PM EDT
Withdrawn Phase 1 Interventional

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

NCT05700630
View directory record Official record
Conditions
HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection, Interleukin
Interventions
FT538, Vorinostat
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

The Learning Registry

NCT03911284
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 23, 2026, 2:17 PM EDT
Not yet recruiting No phase listed Observational

Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE

NCT07594392
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement, Vascular Function Testing
Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting No phase listed Observational

The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study

NCT07315997
View directory record Official record
Conditions
Rheumatoid Arthritis (RA, Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
high sensitivity cardiac troponin
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 79 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Not listed Not applicable Interventional

Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes

NCT04093440
View directory record Official record
Conditions
Metabolic Syndrome, ASCVD, Lifestyle Risk Reduction
Interventions
lifestyle modification
Other
Lead sponsor
Holy Cross Hospital, Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

NCT06267560
View directory record Official record
Conditions
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Interventions
TQJ230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
89
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Not applicable Interventional

Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease

NCT07334834
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider
Other
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

NCT06322641
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

NCT02993120
View directory record Official record
Conditions
Medical Conditions to be Studied, Dyslipidemia, ASCVD Management
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
5,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
118
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 23, 2026, 2:17 PM EDT
Not yet recruiting Phase 2 Interventional

Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD

NCT07654231
View directory record Official record
Conditions
Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
Interventions
Low-dose Colchicine at 0.5mg daily, Usual Care
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 3 Interventional

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774
View directory record Official record
Conditions
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Muvalaplin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
131
States / cities
Apache Junction, Arizona • Gilbert, Arizona • Phoenix, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 2 Interventional

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

NCT07303777
View directory record Official record
Conditions
Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Interventions
ABP-745 Dose A, Placebo, ABP-745 Dose B, ABP-745 Dose C
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Beverly Hills, California • San Diego, California • Torrance, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Not listed Not applicable Interventional

Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes

NCT04862858
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Educational Intervention
Other
Lead sponsor
Humana Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
4,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Jul 23, 2026, 2:17 PM EDT
Completed No phase listed Observational

A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia

NCT06507852
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 3 Interventional

Pelacarsen Roll-over Extension Program

NCT06875973
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Pelacarsen (TQJ230)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
83
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Not yet recruiting Not applicable Interventional

Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)

NCT07355894
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
Interventions
AI-Detected CAC Notification and Care Facilitation
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 74 Years
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Pleasanton, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 2 Interventional

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

NCT06691217
View directory record Official record
Conditions
Vascular Inflammation, ASCVD, ASCVD Management
Interventions
CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jul 23, 2026, 2:17 PM EDT
Recruiting Phase 1 Interventional

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT06451770
View directory record Official record
Conditions
Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
Interventions
VERVE-201
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Clearwater, Florida • Miami Lakes, Florida • Port Orange, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05142722
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT03814187
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions
Inclisiran Sodium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
141
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 23, 2026, 2:17 PM EDT